Quantum BioPharma Reaches 50% Enrollment in Lucid-MS MS Imaging Trial
QNTM•Quantum BioPharma's collaborative imaging study with Massachusetts General Hospital reached 50% patient enrollment in its Lucid-MS multiple sclerosis trial. Preliminary imaging data reveal robust acute MS lesion detection and potential gray matter lesion sensitivity, supporting Lucid-MS's diagnostic development.
1. Midpoint Enrollment Achieved
Quantum BioPharma and Massachusetts General Hospital have enrolled 50% of targeted patients in the pilot imaging study for Lucid-MS, marking a key operational milestone. This achievement confirms recruitment efficacy and allows the team to proceed with planned imaging assessments and interim reviews.
2. Preliminary Imaging Findings
Early imaging analyses demonstrate a strong signal in acute multiple sclerosis lesions and initial indications of sensitivity to gray matter lesions. These findings may enhance Lucid-MS’s potential as a comprehensive diagnostic tool capable of detecting varied lesion types.
3. Next Development Steps
The study will continue to full enrollment, followed by in-depth safety and efficacy evaluations. Positive outcomes could propel Lucid-MS into larger pivotal trials and support future regulatory submissions for diagnostic approval.
